Prospection Secures $45 million to Accelerate Growth
Prospection, has successfully raised $45 million from institutional investors in a Series B round. Corner stoned by new investor Ellerston JAADE with participation from existing shareholders Main Sequence and Horizons Ventures. Prospection uses real world…
Data helping Rare Cancers
An estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred Worldwide in 2020 (GLOBOCAN 2020). In Australia, cancer is the leading cause of health burden. More than 1 million people in…
Impact of a Patient Support Program on patient beliefs about neovascular age-related macular degeneration and persistence to anti-vascular endothelial growth factor therapy
This paper compared persistence between patients prescribed intravitreal aflibercept (IVT-AFL) for neovascular age-related macular degeneration (nAMD) in Australia enrolled on a patient support program (PSP) with that of a sample of patients from the Australian PBS dataset (10% PBS sample); explore predictors of persistence; describe changes in patient beliefs over the course of their enrollment in a PSP for patients treated with IVT-AFL for nAMD; and assess patient satisfaction.
Real World Evidence for Rare disease
Rare disease Day, recognises the 6,000+ identified, often life threatening, rare diseases*. Impacting over 300 million people worldwide, 72% of rare diseases are genetic, with 70% of those starting in childhood*. The low prevalence and…
Prospection launches in Japan
Today, we announce the opening of our Japan headquarters. With the appointment of health informatics and pharmaceutical veteran Kaoru Sato to lead our Japan operations. The new office in Tokyo will enable Prospection to work closely with international pharmaceutical and research partners. Offering the full suite of our health data science capabilities.
Our Founder’s Vision for Healthcare Data Analytics
Prospection has developed into a company that clients can trust to help them achieve success. Our advanced knowledge and expertise in healthcare data analytics supports complex research questions. The experience and expertise of the 3…
Prospection vision and values: A look into the future with CEO Eric Chung
Prospection is a health data analytics company that is currently based in Sydney. In the beginning Prospection started with just 3 people, its founders Eric, Ricky and Peter. 8 years on Prospection has thrived, growing…
A retrospective review of the persistence of bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population
This study aimed to describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients.
Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD)
This paper aimed to describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment).
Cardiometabolic comorbidities and life expectancy in people on medication for schizophrenia in Australia
This study aimed to assess the risks of people on medication for schizophrenia developing different components of the metabolic syndrome and their life expectancy, through reference to a representative population of Australians without schizophrenia.
Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience
This paper aimed to study treatment persistence and mortality using a single-pill, fixed-dose combination tablet compared with a two-pill combination for hypertension.y using a single-pill, fixed-dose combination
tablet compared with a two-pill combination for hypertension.
Are high coronary risk patients missing out on lipid-lowering drugs in Australia?
This study examined whether high coronary risk patients in Australia, where use of lipid-lowering drugs (LLD) is very high by international standards, are receiving LLD.
